Physician
Oncology
Dr. Michelle A. Fanale, MD
|
|
Give Review
Michelle A. Fanale, MD is an expert in the field of Oncology. She went to medical school at Rutgers New Jersey Medical School. Rutgers New Jersey Medical School is ranked 76 in research and 0 in primary care medicine Doctor Michelle A. Fanale, MD is a published doctor. She published 45 publications, including: 'A novel arylsulfatase A protein variant and genotype in two patients with major depression.' Michelle Fanale accepts Medicare.
Publications
- Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.
- Prognostic Factors of Hepatosplenic T-Cell Lymphoma: Clinicopathologic Study of 28 Cases.
- Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
- Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease.
- Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-Cell lymphoma.
- Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory Lymphoma.
- Detection of classical Hodgkin Lymphoma specific sequence in peripheral blood using a next-generation sequencing approach.
- Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease.
- Safety and activity of lenalidomide and rituximab in untreated indolent Lymphoma: an open-label, phase 2 trial.
- Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies.
- Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study.
- Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Lab...
- Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-Cell non-Hodgkin lymphoma.
- (90) Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-Cell lymphomas, including bulky disease.
- Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
- Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive Lymphomas: a retrospective evaluation of safety and efficacy.
- Efficacy and Safety of Antiretrovirals in HIV-Infected Patients with Cancer.
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular Lymphoma: a single group, open-label, phase 2 trial.
- The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin Lymphoma.
- Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse larg...
- Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic Cell transplant.
- Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma.
- Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody Lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin Lymphoma.
- Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's Lymphoma: a phase 1, open-label, dose-escalation study.
- Oral lenalidomide with rituximab in relapsed or refractory diffuse large Cell, follicular and transformed lymphoma: a phase II clinical trial.
- High-dose chemotherapy and Autologous Stem Cell Transplantation For Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).
- Zoledronic acid for prevention of bone loss in patients receiving primary therapy for Lymphomas: a prospective, randomized controlled phase III trial.
- Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Sub...
- Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/R...
- A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-Cell lymphoma: a phase 1/2 clinical trial.
- Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed Lymphoma.
- A Phase 1 Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies.
- Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem Cell transplant in relapsed and refractory Hodgkin lymphoma: pre...
- Nodular lymphocyte predominant Hodgkin's Lymphoma.
- Treatment of metastatic breast Cancer with trastuzumab and vinorelbine during pregnancy.
- Evaluating the WEB training program for Cancer screening in Native American women.
- Some unusual complications of malignancies: case 2. Marantic endocarditis in advanced Cancer.
- Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast Cancer cells.
- Monoclonal antibodies in the treatment of non-Hodgkin''s Lymphoma.
- Induction of apoptosis in human lung Cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53.
- Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin Lymphoma.
- Mocetinostat for relapsed classical Hodgkin's Lymphoma: an open-label, single-arm, phase 2 trial.
- A novel arylsulfatase A protein variant and genotype in two patients with major depression.
Schools
UmdnjNew Jersey Med Sch
Procedures Preformed
- Plasmapheresis
- Prostate Cancer Screening Exam (DRE)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
Mayo School of Graduate Medical Education -
Rutgers New Jersey Medical School
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1871689463 | |
| NPPES Provider LastName | FANALE | |
| NPPES Provider FirstName | MICHELLE | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 233.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1871689463 |
| Last Name Of The Provider | FANALE |
| First Name Of The Provider | MICHELLE |
| View All |
Similar Doctors
|
|
Dr. Fredrick B. Hagemeister, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Craig A. Kovitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sumit K. Subudhi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Riad O. El Fakih, MD |
|
|
Dr. Julie A. Ellerhorst, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Rakesh C. Mehra, MD |
|
|
Dr. Florencia M. McAllister, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Brian M. Thomas |
|
|
Dr. Henry I. Zaleski Jr., MD
This Doctor is OpenDoctor Recommended.
|